Inclacumab

CAS No. 1256258-86-2

Inclacumab( —— )

Catalog No. M37165 CAS No. 1256258-86-2

Inclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 453 Get Quote
5MG 687 Get Quote
10MG 937 Get Quote
25MG 1371 Get Quote
50MG 1812 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Inclacumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Inclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM.
  • Description
    Inclacumab (Anti-Human selectin P Recombinant Antibody) is a humanized monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.
  • In Vitro
    Inclacumab (0.4-40 μg/mL; 5 min) significantly reduces flow adhesion of P-Selectin with Whole Blood (WB) and isolated White Blood Cell (I-WBC) and shows a morestronger effect on isolated white cells.Inclacumab shows great binding affinity to P-selectin with a Kd value of 9.9 nM.Inclacumab inhibits PSGL-1 mimetic peptide binding with P-selectin with an IC50 value of 1.9 μg/mL.Inclacumab blocks the adhesion of PSGL-1 expressing cells to an immobilized P-selectin with an IC50 value of 430 ng/mL.Inclacumab (0-100 μg/mL; 5min) dose-dependently inhibits thrombin receptor-activating peptide (TRAP)-induced platelet-leukocyte aggregates (PLA) levels with an IC50 value of 1.4 μg/mL.
  • In Vivo
    Inclacumab (4 mg/kg; s.c. once) reduces TRAP- and ADP-induced PLA levels in cynomolgus monkeys.Inclacumab (2-50 mg/kg; i.v.; once a week for 13 weeks) inhibits TRAP induced PLA levels in cynomolgus monkeys.Animal Model:Cynomolgus monkeys Dosage:4 mg/kg Administration:Subcutaneous injection; 4 mg/kg; once Result:Significantly reduced TRAP-induced PLA levels from 25% to 6% and supressed PLA formation ≥80% for at least 28 days post treatment. Remained plasma concentrations >20 μg/mL during post treatment for 28 days. Significantly inhibited the formation of ADP (10 μM)-induced PLAs.Animal Model:Cynomolgus monkeys Dosage:2, 10, and 50 mg/kg Administration:Intravenous injection; once daily; for 13 weeks Result:Inhibited TRAP-induced PLA and remained concentrations at all three dose levels are higher than 20 μg/mL. Persisted the full inhibition of PLA formation between dosing period.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1256258-86-2
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tarasev M, et al. S107: P-SELECTIN INHIBITOR INCLACUMAB REDUCES CELL ADHESION IN AN IN-VITRO ASSAYS SHOWING POTENTIAL FOR PREVENTION OF VASO-OCCLUSION EVENTS IN SICKLE CELL DISEASE. Hemasphere. 2022 Jan 31;6(Suppl ):3-4.
molnova catalog
related products
  • Cimifugin 4-O-beta-D...

    Cimifugin 4'-O-beta-D-glucopyranoside is a natural product.

  • Ajugasterone C

    Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to carrageenan-induced inflammation in Sprague Dawley rats.

  • Spinosyn A

    Spinosyn A is a polyketide-derived macrolide produced by Saccharopolyspora spinosa and is an active ingredient in several commercial insecticides.